A weighted method for estimation of receptor occupancy for pharmacodynamic measurements in drug development

被引:5
|
作者
Sternebring, Ola [1 ]
Alifrangis, Lene [1 ]
Christensen, Toke Folke [2 ]
Ji, Hong [3 ]
Hegelund, Anne Charlotte [4 ]
Hogerkorp, Carl-Magnus [3 ]
机构
[1] Novo Nordisk AS, Dept Dev DMPK, DK-2760 Malov, Denmark
[2] Novo Nordisk AS, Dept Quantitat Clin Pharmacol, DK-2860 Soborg, Denmark
[3] Novo Nordisk AS, Dept Pharmacodynam, Novo Nordisk Pk, DK-2760 Malov, Denmark
[4] Novo Nordisk AS, Dept Dev Bioanal, DK-2760 Malov, Denmark
关键词
receptor occupancy; pharmacodynamics; flow cytometry; biomarker; clinical trial; drug development; RESEARCH-AND-DEVELOPMENT; MONOCLONAL-ANTIBODY; PHASE-I; RHEUMATOID-ARTHRITIS; CLINICAL ACTIVITY; HEALTHY-SUBJECTS; DOUBLE-BLIND; SAFETY; PHARMACOKINETICS; TRIAL;
D O I
10.1002/cyto.b.21277
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BackgroundFlow cytometry-based receptor occupancy (RO) assessments for pharmacodynamic (PD) response measurements along with drug pharmacokinetic (PK) measurements represent a cornerstone in mechanism based PK/PD modeling of drugs against cell surface targets. This report describes the utility of using a Free and a Bound assay in combination to derive RO estimations through a weighted calculation method. MethodsData from a RO assay validation study in human samples was used to explore the performance of various RO data calculation methods. The calculation methods were subsequently applied to investigate the best method to generate RO data in a first in human phase 1 clinical trial. Finally, the outcome of the analysis was used for PK/PD modeling of a prospective phase 2a trial. ResultsThe validation data assessment demonstrated that a weighted RO calculation method had a better performance in terms of precision, accuracy and dynamic range. In the phase 1 clinical trial data analysis the weighted method again demonstrated a better performance resulting in a more robust RO estimation, and subsequently also generating a more reliable PK/PD simulation for the phase 2a trial. ConclusionsThis report demonstrated the utility of using a combined Free and Bound RO assessment together with a weighted calculation method to better support mechanism-based PK/PD modeling activities. (c) 2015 International Clinical Cytometry Society
引用
收藏
页码:220 / 229
页数:10
相关论文
共 50 条
  • [1] Multiplexing of receptor occupancy measurements for pharmacodynamic biomarker assessment of biopharmaceuticals
    Vainshtein, Inna
    Schneider, Amy K.
    Sun, Bo
    Schwickart, Martin
    Roskos, Lorin K.
    Liang, Meina
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2016, 90 (02) : 128 - 140
  • [2] Likelihood estimation of drug occupancy - generalization to multiple occupancy measurements
    Ilhan, A.
    Zanderigo, F.
    Ogden, R. T.
    Knudsen, G.
    Svarer, C.
    Schain, M.
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2019, 39 : 102 - 103
  • [3] Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development
    Liang, Meina
    Schwickart, Martin
    Schneider, Amy K.
    Vainshtein, Inna
    Del Nagro, Christopher
    Standifer, Nathan
    Roskos, Lorin K.
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2016, 90 (02) : 117 - 127
  • [4] Likelihood estimation of drug occupancy for brain pet studies - generalization to multiple occupancy measurements
    Ilhan, A.
    Zanderigo, F.
    Ogden, R. T.
    Knudsen, G. M.
    Svarer, C.
    Schain, M.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S524 - S525
  • [5] Receptor Occupancy Imaging Studies in Oncology Drug Development
    Ingrid J. G. Burvenich
    Sagun Parakh
    Adam C. Parslow
    Sze Ting Lee
    Hui K. Gan
    Andrew M. Scott
    [J]. The AAPS Journal, 20
  • [6] Receptor Occupancy Imaging Studies in Oncology Drug Development
    Burvenich, Ingrid J. G.
    Parakh, Sagun
    Parslow, Adam C.
    Lee, Sze Ting
    Gan, Hui K.
    Scott, Andrew M.
    [J]. AAPS JOURNAL, 2018, 20 (02):
  • [7] Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab
    Wyant, Tim
    Estevam, Jose
    Yang, Lili
    Rosario, Maria
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2016, 90 (02) : 168 - 176
  • [8] Guidelines to PET measurements of the target occupancy in the brain for drug development
    Takano, Akihiro
    Varrone, Andrea
    Gulyas, Balazs
    Salvadori, Piero
    Gee, Antony
    Windhorst, Albert
    Vercouillie, Johnny
    Bormans, Guy
    Lammertsma, Adriaan A.
    Halldin, Christer
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (12) : 2255 - 2262
  • [9] Guidelines to PET measurements of the target occupancy in the brain for drug development
    Akihiro Takano
    Andrea Varrone
    Balázs Gulyás
    Piero Salvadori
    Antony Gee
    Albert Windhorst
    Johnny Vercouillie
    Guy Bormans
    Adriaan A. Lammertsma
    Christer Halldin
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 2255 - 2262
  • [10] Quantitative PET Imaging in Drug Development: Estimation of Target Occupancy
    Mika Naganawa
    Jean-Dominique Gallezot
    Samantha Rossano
    Richard E. Carson
    [J]. Bulletin of Mathematical Biology, 2019, 81 : 3508 - 3541